Group 1 - The Hong Kong innovation drug sector has recorded a three-day consecutive rise since the beginning of 2026, with a rebound of approximately 10% in the main innovation drug index [1][8] - The Hong Kong Innovation Drug ETF (520880) has accumulated a gain of 9.24% since the start of the year, with a notable increase of over 3.4% on January 7 [1][8] - In 2025, the innovation drug sector represented by Hong Kong stocks saw an overall increase of over 60%, becoming a significant player in the market [3][11] Group 2 - The surge in the innovation drug sector at the beginning of 2025 is attributed to multiple catalysts, including favorable policies, better-than-expected industry data, and the approach of important industry conferences [5][13] - Significant developments include the approval of the first domestically produced CTLA-4 inhibitor "Daboshu" by Innovent Biologics and the approval of TROP2 ADC "Dercutuzumab" for breast cancer by AstraZeneca and Daiichi Sankyo, enhancing the ADC sector's competitive edge [5][13] - The total amount of outbound licensing for Chinese innovative drugs reached $135.655 billion in 2025, with 157 transactions, both setting historical records [5][13] Group 3 - The sector's valuation is currently at a relatively low level following previous adjustments, and there has been a noticeable inflow of funds driven by strong fundamental data [6][14] - Investment outlook for 2026 focuses on innovation and international expansion, with an emphasis on companies that have achieved significant business development (BD) transactions and those with unexpected overseas clinical progress [6][14] - The industry is entering a "dual-driven" 3.0 era of product development and commercial sales, with a clear upward trend in demand for next-generation therapies such as ADCs and dual antibodies [6][14] Group 4 - New technologies such as AI in drug development and brain-computer interfaces are expected to accelerate industrialization due to supportive policies and pricing [7][15] - Areas facing potential recovery include medical device exports, consumer healthcare, and OTC traditional Chinese medicine, which may present wave-like investment opportunities under improving policies or macroeconomic conditions [7][15] - The investment logic in the pharmaceutical sector for 2026 has shifted from broad-based gains to selective alpha strategies, favoring companies with robust technology and clear commercialization paths [7][15]

Group 1 - The A-share pharmaceutical sector has significantly outperformed the market, with leading innovative drug company Rongchang Bio surging over 11% [1][8] - The medical sector has shown some divergence, with the brain-computer interface concept maintaining its popularity, as evidenced by Meihao Medical achieving a 20% limit-up for three consecutive days [1][8] - The largest medical ETF in the market (512170) has been climbing towards its six-month moving average, reaching a new 20-day high [1][8] Group 2 - In the Hong Kong market, the overall index has retreated by about 1%, but the pharmaceutical sector has risen against the trend, with the high-volatility Hong Kong Innovation Drug ETF (520880) increasing by 3.42% and achieving a trading volume of 6.91 billion yuan, the highest in nearly two months [2][9] - Among the 37 innovative drug companies covered, 33 saw their stock prices rise, with Rongchang Bio in Hong Kong soaring nearly 13% [2][9] - The CXO concept stocks, including Kailaiying and Tigermed, both rose nearly 9%, contributing to a 3.14% increase in the Hong Kong medical theme index [4][9] Group 3 - Recent catalysts in the pharmaceutical field include the approval of Innovent Biologics' CTLA-4 monoclonal antibody "Daboshu" for domestic use, filling a gap in the dual immune new adjuvant therapy field [11] - A significant collaboration worth over 2 billion USD between Gakos and AstraZeneca has set a record for domestic clinical-stage small molecule cancer drug partnerships [11] - Analysts from various brokerages, including Pacific Securities and Guotai Junan, have expressed bullish views on the innovative drug and medical device industry chain, recommending continued focus on this sector [11][12] Group 4 - The upcoming launch of the Hong Kong medical ETF Huabo (159137) on January 12 is expected to attract attention as it tracks the Hong Kong medical theme index [4][11] - The strategy for the pharmaceutical sector emphasizes "innovation + internationalization" as the core theme for 2026, with a focus on innovative drugs and the medical device industry [11][12] - If consumer sentiment improves, the consumer medical sector, including medical services and OTC traditional Chinese medicine, is expected to enter a recovery phase [11]

Group 1 - The Hong Kong innovative drug sector has recorded a three-day consecutive rise since the beginning of 2025, with a rebound of approximately 10% in the main innovative drug index [1][3] - The Hong Kong innovative drug ETF (520880) has accumulated a gain of 9.24% since the start of the year, with a daily increase of over 3.4% [1] - In 2025, the Hong Kong innovative drug sector has shown an overall increase of over 60%, becoming a significant player in the market, despite experiencing a notable pullback in Q4 [3][4] Group 2 - The innovative drug sector's strong performance in early 2025 is attributed to favorable policies, exceeding industry data expectations, and the approach of significant industry conferences [6] - The total amount of outbound licensing for Chinese innovative drugs reached $135.655 billion in 2025, with 157 transactions, both setting historical records [6] - The number of new drug pipelines under research in China accounts for 30% of the global total, ranking second worldwide [6] Group 3 - Investment outlook for 2026 focuses on innovation and international expansion, with an emphasis on companies that have achieved significant business development transactions and overseas clinical progress [7] - The innovative drug industry is entering a "dual-driven" phase of product development and commercial sales, highlighting the importance of next-generation therapies such as ADCs and dual antibodies [7] - The AI pharmaceutical sector and brain-computer interfaces are expected to accelerate industrialization due to clear policy development paths and insurance pricing support [8] Group 4 - The investment logic in the pharmaceutical sector for 2026 has shifted from broad market increases to selective alpha investments, favoring companies with strong technology and clear commercialization paths [8] - Relevant ETFs include the Hong Kong innovative drug ETF (520880), drug ETF (562050), and medical ETF (512170) [8]

Core Viewpoint - The Hong Kong innovative drug sector continues its strong performance, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising over 2%, indicating a bullish trend in the market [1] Industry Dynamics - Research Development: Innovent Biologics has received approval for its CTLA-4 monoclonal antibody "Daboshu" as the first domestically approved CTLA-4 inhibitor, filling a gap in the domestic dual immune new adjuvant therapy field [1] - Business Development: Ginkgo Bioworks has established a collaboration with AstraZeneca worth over $2 billion, setting a record for domestic clinical-stage small molecule anti-cancer drug collaborations [1] Market Activity - The Hong Kong Stock Connect Innovative Drug ETF managed by E Fund (159316) saw a significant increase in trading volume, exceeding 600 million yuan, indicating heightened investor interest [1] - The market's expectations for a potential interest rate cut by the Federal Reserve have increased, with the probability of a rate cut in March 2026 rising to over 40%, which may positively impact the Hong Kong innovative drug sector [1]

Market Performance - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) experienced a strong rebound today, rising by 3.3% with a trading volume increasing to 500 million [1] Core Drivers - Liquidity expectations have improved as the U.S. December non-farm payroll data fell short of expectations, leading to heightened market anticipation for a Federal Reserve interest rate cut, with the CME "FedWatch" indicating a 40.7% probability of a rate cut in March [2] Industry Updates - Research and Development Progress: Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved for market launch as the first domestic drug of its kind [2] - Business Development Activity: GSK has entered into a collaboration with AstraZeneca worth over $2 billion, setting a record for domestic clinical-stage small molecule anti-cancer drug collaborations. The total transaction amount for outbound licensing in 2025 is projected to reach $135.655 billion [2]

Core Viewpoint - The Hong Kong stock market's innovative drug sector has shown significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% and 36 out of 37 covered companies reporting gains, indicating a strong performance in the sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a rapid increase of over 3.6% [1] - 36 out of the 37 innovative drug companies covered by the ETF reported positive performance, with Syncona Health-B leading with a surge of over 13% [1] - Major player Kangfang Biologics saw an increase of nearly 5% [1] Group 2: Regulatory Approvals and Developments - Innovent Biologics' CTLA-4 monoclonal antibody "Daboshu" became the first domestically approved CTLA-4 inhibitor, filling a gap in the dual immune new adjuvant therapy field in China [1] - AstraZeneca and Daiichi Sankyo's TROP2 ADC "Dercutuzumab" received approval for breast cancer indications, further solidifying the advantages in the ADC sector [1] Group 3: Industry Trends and Projections - The innovative drug business development (BD) transactions are on the rise, with the total authorization amount for Chinese innovative drugs reaching $135.655 billion and 157 transactions recorded in 2025, both setting historical highs [1] - China's pipeline of new drugs now accounts for 30% of the global total, ranking second worldwide [1] - Analysts suggest that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation restructuring expected by 2026 [1][2] Group 4: Investment Strategies - Huafu Securities maintains that the long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance indicating good opportunities for innovative drugs and devices in 2026 [2] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: pure focus on innovative drugs, significant weight on leading companies, and better risk control [2] - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF (562050) and its associated fund (024986) are recommended, which focus on the top 50 A-share pharmaceutical companies and include a significant portion of traditional Chinese medicine [2][3]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector has seen a resurgence, with the high-volatility Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% on January 7, 2023, and 36 out of 37 covered innovative drug companies showing positive performance [1][7]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) quickly surged by 3.61%, reaching a price of 0.545 [2][7]. - Among the covered companies, Tongyu Pharmaceutical-B soared over 13%, while the leading company, Kangfang Biopharmaceutical, increased nearly 5% [1][7]. Group 2: Industry Developments - Innovative drug business development (BD) transactions are continuing to grow, with the total amount of outbound licensing for Chinese innovative drugs expected to reach $135.655 billion by 2025, marking a historical high with 157 transactions [3][9]. - China's pipeline of new drugs currently accounts for 30% of the global total, ranking second worldwide [3][9]. - The biopharmaceutical industry is entering a critical phase of innovation realization and global layout, with a potential performance inflection point and valuation restructuring expected by 2026 [3][9]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated fund (025221) track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies (over 73% in the top ten), and has controlled risks by reducing the weight of less liquid stocks [3][9]. - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF in the market (562050) and its associated fund (024986) focus on the top 50 A-share pharmaceutical companies, with approximately 60% in innovative drugs and 25% in traditional Chinese medicine [4][10].

Core Insights - The Hong Kong innovation drug sector has shown a significant recovery, with the Hang Seng Innovation Drug Index rising by 4.5% as of 14:00, driven by strong performances from key stocks such as InnoCare Pharma-B, which increased by over 10% [1] - Recent breakthroughs in innovative drug development include the approval of the first domestically developed CTLA-4 inhibitor, "Daboshu," by Innovent Biologics, and the approval of the TROP2 ADC "Trastuzumab Deruxtecan" for breast cancer by AstraZeneca and Daiichi Sankyo, enhancing the competitive landscape of ADCs [1] - The volume of business development (BD) transactions in innovative drugs continues to grow, with a record total authorization amount of $135.655 billion and 157 transactions in 2025, highlighting significant market activity [1] - Notable licensing deals include the $2 billion authorization of CBP-1018 by Tongyi Pharmaceutical and a $1.06 billion deal for the ADC drug SIM0613 by Ascletis, along with a collaboration exceeding $2 billion between Gossamer Bio and AstraZeneca for a pan-KRAS inhibitor [1] - Pacific Securities indicates that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation reshaping expected by 2026 [1] Industry Overview - The Hang Seng Innovation Drug Index is the first "pure" innovation drug index with 100% purity, focusing on leading companies in the Hong Kong innovation drug sector [2] - The E Fund Innovation Drug ETF (159316) is currently the only product tracking this index, providing investors with a streamlined way to capitalize on investment opportunities in the sector [2]

Core Viewpoint - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) has shown a strong rebound, rising over 4.5% in early trading, indicating positive market sentiment towards innovative drug development in China [1] Group 1: Innovative Drug Development - Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved as the first domestic drug of its kind, filling a gap in the market [1] - The TROP2 ADC "Dercumab" jointly developed by AstraZeneca and Daiichi Sankyo has been approved for breast cancer indications in China, strengthening the ADC sector [1] Group 2: Business Development (BD) Growth - By December 31, 2025, the total transaction amount for China's innovative drug BD overseas licensing is expected to reach $135.655 billion, with upfront payments of $7 billion and a total of 157 transactions, marking historical highs across various metrics [1] - Recent BD transactions include: - Tongyi Medicine's peptide-conjugated drug CBP-1018 for prostate cancer licensed to MultiValent Biotherapies for $2 billion [1] - Ascletis Pharma's ADC drug SIM0613 licensed to Ipsen for $1.06 billion [1] - GRAIL's pan-KRAS inhibitor entering a Co-Co collaboration with AstraZeneca for over $2 billion, setting a record for clinical-stage small molecule collaborations [1] Group 3: Key Products - E Fund's Hong Kong Stock Connect innovative drug ETF (159316, linked A/C: 024328/024329) [1] - E Fund's Hong Kong Stock Connect pharmaceutical ETF (513200, linked A/C: 018557/018558) [1] - E Fund's Hang Seng Biotechnology ETF (159105) [1]

Group 1 - The innovative drug ETF Guotai (517110) rose over 2.6%, with a focus on innovative therapies and internationalization progress [1] - The chemical pharmaceutical sector performed moderately, while the innovative drug field saw multiple advancements, including Heng Rui Medicine's cMET ADC new drug SHE-1826 being proposed for breakthrough therapy designation [1] - Innovent Biologics' CTLA-4 biosimilar Daborhizumab is priced at 13,100 yuan per unit, and Zai Lab's DLL3/DLL3/CD3 tri-antibody received a $1.235 billion licensing deal with AbbVie, including an upfront payment of $100 million and up to $1.075 billion in milestone payments [1] Group 2 - Technological advancements in ADC, IO dual antibodies, GLP-1 weight loss, and small nucleic acid drugs are progressing, enhancing China's innovative drug internationalization capabilities [1] - The policy environment shows stabilization in medical insurance negotiations, with the introduction of a "commercial insurance innovative drug catalog" in 2025 to expand market opportunities, and the optimization of rules in the 11th batch of centralized procurement to alleviate fierce competition [1] - The CXO sector is experiencing growth in overseas orders and a recovery in domestic demand, with rapid increases in demand for ADC and peptide drugs [1] Group 3 - The medical device sector is focusing on performance recovery and overseas opportunities, with Hong Kong stocks highlighting the profit release of leading companies in niche segments, and new technologies like brain-computer interfaces and AI medical applications gaining investment interest due to policy support [1] - The traditional Chinese medicine sector is influenced by respiratory diseases and progress in the basic drug catalog, while the biopharmaceutical field is paying attention to the expectations of innovative pipeline authorizations and sales improvements for vaccine companies [1]